In a report published on Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Alnylam Pharmaceuticals ALNY with an Overweight rating and a price target of $35.
In the report, Morgan Stanley stated, "We view Alnylam as the leader in RNAi drug development. The components of this technology platform (i.e. drug delivery, drug composition, target selection) have progressed to the point where we have high confidence in the ability to move from a science based company to a commercial one."
Alnylam Pharmaceuticals closed on Monday at $30.75.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
